Sotyktu (deucravacitinib) Letter of Medical Necessity
Sotyktu (deucravacitinib) is the first FDA-approved TYK2 inhibitor, offering a novel oral mechanism for moderate-to-severe plaque psoriasis. Unlike JAK inhibitors, it lacks FDA boxed warnings for MACE, VTE, malignancy, and mortality. PA denials commonly involve step-therapy requirements through biologics or apremilast — a well-written LMN documenting prior therapy failures and the clinical rationale for TYK2-selective inhibition is key.
FDA-Approved Indications
- ● moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Why Sotyktu Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy not completed — TNF inhibitor or IL-17/IL-23 biologic not tried first
- 2. PASI score or BSA not documented at baseline
- 3. Oral agent (Otezla) step therapy required before TYK2 inhibitor on many plans
- 4. Diagnosis not confirmed as moderate-to-severe (PASI >12 or BSA >10% required)
- 5. Specialty pharmacy not enrolled (SOTYKTU REMS not required, but SP routing enforced)
- 6. Quantity limit or titration period not addressed
What to Include in a Sotyktu Letter of Medical Necessity
Document plaque psoriasis diagnosis with baseline severity (PASI score ≥12, BSA ≥10%, or IGA ≥3), prior conventional therapy trials (methotrexate, cyclosporine, acitretin) with documented inadequate response or intolerance, prior biologic or apremilast trial history if step therapy applies, absence of contraindications, and the clinical rationale for oral vs injectable therapy — particularly relevant for patients with needle aversion, infection risk precluding biologics, or psoriasis confined to areas limiting biologic eligibility.
Key clinical evidence to cite:
- ✓ POETYK PSO-1 and PSO-2 Phase 3 trials — PASI 75 response ~53% vs 9% placebo at week 16
- ✓ POETYK PSO-LONG — maintained response through 2 years
- ✓ Head-to-head vs apremilast (Otezla): superior PASI 75 at week 16 (53% vs 40%)
- ✓ First-in-class TYK2 inhibitor — novel mechanism distinct from JAK inhibitors (no boxed warning for MACE/VTE)
Relevant guidelines:
- 📖 AAD-NPF 2019 Psoriasis Guidelines (updated 2023)
- 📖 GRAPPA 2021 PsA Recommendations
- 📖 American Academy of Dermatology TYK2 Inhibitor Guidance 2023
Sotyktu Prior Authorization Criteria
Standard criteria across major US payers for Sotyktu. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy not completed — TNF inhibitor or IL-17/IL-23 biologic not tried first
- → Oral agent (Otezla) step therapy required before TYK2 inhibitor on many plans
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Sotyktu
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Sotyktu Prior Authorization FAQ
Why was my Sotyktu prior authorization denied?
The most common denial reasons for Sotyktu are: Step therapy not completed — TNF inhibitor or IL-17/IL-23 biologic not tried first; PASI score or BSA not documented at baseline; Oral agent (Otezla) step therapy required before TYK2 inhibitor on many plans; Diagnosis not confirmed as moderate-to-severe (PASI >12 or BSA >10% required); Specialty pharmacy not enrolled (SOTYKTU REMS not required, but SP routing enforced); Quantity limit or titration period not addressed.
What should a Sotyktu Letter of Medical Necessity include?
Document plaque psoriasis diagnosis with baseline severity (PASI score ≥12, BSA ≥10%, or IGA ≥3), prior conventional therapy trials (methotrexate, cyclosporine, acitretin) with documented inadequate response or intolerance, prior biologic or apremilast trial history if step therapy applies, absence of contraindications, and the clinical rationale for oral vs injectable therapy — particularly relevant for patients with needle aversion, infection risk precluding biologics, or psoriasis confined to areas limiting biologic eligibility.
Which payers cover Sotyktu?
Sotyktu is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.